The current situation of oncology drug lag in Japan and strategic approaches for pharmaceutical companies

Drug Information Journal

Volumn 43, Issue 6, 2009, Pages 757-765

  Hashimoto, Junichi ^a,b   Ueda, Eiji ^a   Narukawa, Mamoru ^b  

^a PFIZER INC   (United States)

^b KITASATO UNIVERSITY   (Japan)

Author keywords

Clinical trial; Drug lag; Foreign data; Global development; Oncology; PMDA

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; ERLOTINIB; PEMETREXED; SORAFENIB; SUNITINIB;

DECISION MAKING; DRUG APPROVAL; DRUG INDICATION; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; GOVERNMENT REGULATION; HUMAN; JAPAN; PRIORITY JOURNAL; PROCESS DEVELOPMENT; RESOURCE ALLOCATION; REVIEW;

EID: 72149117103     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286150904300613     Document Type: Review

References (35)

1. Fukuhara H. JPMA Research Paper Series (in Japanese). 2006; No.31. Available at: http://www.jpma.or.jp/opir/research/paper-31.pdf. Accessed March 2008.
2. Evaluation report of bevacizumab by the Working Group of the Minister's Special Committee on Un-approved Drugs (in Japanese). Available at: http://www.mhlw.go.jp/shingi/2005/07/dl/s0722-6c1.pdf. Accessed March 2008.
3. Evaluation report of sunitinib by the Working Group of the Minister's Special Committee on Un-approved Drugs (in Japanese). Available at: http://www.mhlw.go.jp/shingi/2006/07/dl/s0728-10b.pdf. Accessed March 2008.
4. Drug approval and licensing procedures in Japan 2005. Jiho, Inc. 2005: 689-690.
5. Yasuda K, Ono S. New drug review period in Japan (in Japanese). JPMA Research Paper Series No. 37. Available at: http://www.jpma.or.jp/opir/research/ paper-39.pdf. Accessed June 2008.
6. Narukawa M. Early Approval and launch of new drugs: dissolution of drug lag. Clin Eval. 2006;33(Suppl 23):315-319. Slides for the presentation are available at: http://www.pharm.kitasato-u.ac.jp/biostatis/presentation2005/26/ Session6/05Mr-Narukawa-draft.pdf. Accessed March 2008.
7. Takahashi K. Drug development in Japan: opportunities and challenges in drug development. Int J Pharm Med. 2007;21(5):331-338. (Pubitemid 47416283)
8. Shimatani K. International competitiveness of Japanese clinical trials on cost and performance. Clin Eval 2006;33(Suppl 23):45-58.
9. JPMA website (in Japanese). Available at: http://www.jpma.or.jp/medicine/ about-rnedicine/about.html. Accessed June 2008.
10. McCurry J. Japan unveils 5-year plan to boost clinical research. Lancet. 2007;369:1333-1336. (Pubitemid 46923611)
11. March 2006 GAO Report Drug Safety. Available at: http://www.gao.gov/new. items/d06402.pdf#search='May%202006%20GAO%20report%20OND%20CDER'. Accessed October 2008.
12. PMDA review report of sorafenib (in Japanese). Available at: http://www.info.pmda.go.jp/shinyaku/g080105/630004000-22000AMX00014000-A100-1. pdf. Accessed June 2008.
13. PMDA review report of erlotinib (in Japanese). Available at: http://www.info.pmda.go.jp/shinyaku/g071008/45004500-21900AMX01758-A100-1.pdf. Accessed June 2008.
14. PMDA review report of bevacizumab (in Japanese). Available at: http://www.info.pmda.go.jp/shinyaku/g070408/450045000-21900AMX00910-A105-1.pdf. Accessed June 2008.
15. Minutes of the Special Committee for Evaluation of Anti-Cancer Drugs in Combination Therapy (in Japanese). Available at: http://www.mhlw.go.jp/shingi/ 2005/02/s0207-8.html. Accessed March 2008.
16. Minutes and materials of the Minister's Special Committee on Un-approved Drugs (in Japanese). Available at: http://www.mhlw.go.jp/shingi/2005/01/s0124-9. html. Accessed March 2008.
17. Ministry of Health, Labour and Welfare. Japan guidelines for clinical evaluation of anti-cancer drugs (in Japanese). November 2005. Available at: http://wwwhourei.mhlw.go.jp/hourei/doc/tsuchi/171101-b.pdf. Accessed March 2008.
18. The proposal by the Council for Science and Technology Policy (in Japanese). December 2006. Available at: http://www8.cao.go.jp/cstp/output/ iken061225-1.pdf. Accessed March 2008.
19. The five-year plan for activating clinical trials (in Japanese). Available at: http://www.mhlw.go.jp/shingi/2007/03/dl/s0330-5a.pdf. Accessed March 2008.
20. Ministry of Health, Labour and Welfare. The five-year strategy for creating innovative pharmaceuticals and medical devices (in Japanese). April 2007. Available at: http://www.mhlw.go.jp/houdou/2007/04/dl/h0427-3b.pdf. Accessed March 2008.
21. Cancer Information Service. History of cancer control in Japan. Available at: http://ganjoho.ncc.go.jp/public/statistics/backnumber/odjrh3000000o8is-att/ cancer.pdf. Accessed March 2008.
22. Ministry of Health, Labour and Welfare. Final report of the Committee for Expediting Supply of Effective and Safe New Drugs (in Japanese). July 2007. Available at: http://www.mhlw.go.jp/shingi/2007/07/dl/s0730-10a.pdf. Accessed March 2008.
23. Ministry of Health, Labour and Welfare. Basic principles on global clinical trials. September 2007. Available at: http://www.pmda.go.jp/operations/ notice/2007/file/0928010-e.pdf. Accessed March 2008.
24. Final report of the Special Committee on Clinical Trials (in Japanese). September 2007. Available at: http://www.mhlw.go.jp/shingi/2007/09/s0919-8.html. Accessed March 2008.
25. Points to be considered by the review staff involved in the evaluation process of new drugs. Available at: http://www.pmda.go.jp/english/services/ reviews/file/points.pdf. Accessed June 2008.
26. The 7th Kitasato University-Harvard School of Public Health Symposium. Available at: http://www.pharm.kitasato-u.ac.jp/biostatis/Khsympo-main2006.html. Accessed June 2008.
27. Anti-Tumor Drug Development Forum. Available at: http://atdd-frm.umin.jp/ . Accessed June 2008.
28. Miyajima A. Role of Japan and Asian countries in global pharmaceutical development. 2006 Symposium of Asia Pacific Economic Conference (APEC), October 12, 2006. Available at: http://c11bw1rt.securesites.net/apec2006ph/presen/1012/ 03.pdf. Accessed June 2008.
29. Ueda E, Hashimoto J. Prerequisites for participation in global clinical trials: how to exercise ingenuity in phase 1 trials. Pharm Regul Sci. 2007;38(6):397-401.
30. Mori K. Global development: Japanese efforts and views. Available at: http://c11bw1rt.securesites.net/apec2006ph/presen/1013/12.pdf. Accessed June 2008.
31. Tohkin M. Study Group on Ethnic Factors in Clinical Data from East Asian Populations. Available at: http://www2.convention.co.jp/eaprs2008ph/presen/0415- 10.pdf. Accessed June 2008.
32. Myrand SP, Sekiguchi K, Man MZ, et al. Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. Clin Pharmcol Ther. 2008; Jan 30 [E-pub].
33. Genetic polymorphisms and haplotypes of major drug metabolizing enzymes in East Asians and their comparison with other ethnic populations. Curr Pharmacogenom. 2007;5(1):49-78.
34. Nagata TD. Global clinical trials and development: EFPIA Japan's perspective. Available at: http://www2.convention.co.jp/eaprs2008ph/presen/0415- 04.pdf. Accessed June 2008.
35. Cancer Statistics in Japan '07. Available at: http://ganjoho.ncc.go.jp/ public/statistics/backnumber/2007-en.html. Accessed June 2008.